The Clinical Core provides an important and integral component of CFAR, bringing basic science and rational drug design and development with human volunteer studies. The Clinical Core has three facility components of importance; there are two clinical research environments (the UAB-AIDS Ambulatory Care Clinic and the UAB General Clinical Research Center) and the Clinical Laboratory Core (see description of facilities). In these environments, volunteers will be evaluated prospectively on pharmacokinetics, therapeutics and in vivo pathogenesis studies. Data management and retrieval as well as specimen storage will be standardized for CFAR investigators. Clinical studies will be performed with Institutional Review Board approval.
The Specific Aims for this Clinical Core are: 1. To provide a mechanism for CFAR investigators to obtain specimens (tissue, cells, body fluids, etc.) from consenting volunteers who are evaluated serially and prospectively for basic research studies. 2. To maintain resources of determining drug pharmacokinetics, including metabolism, disposition, clearance and modeling. 3. To make available all identification facilities for evaluation of a consenting patient by CFAR investigators. 4. To develop the Clinical setting for performance of drug evaluations of locally developed therapeutics as well as national therapeutic priorities including Phase I pharmacokinetics and Phase II, III controlled trials for consenting volunteers. 5. To provide contemporary biostatistical resources for data management, data retrieval, pharmacokinetic modeling and study design. 6. To develop novel approaches for allowing translation of developments in the drug targeting core and vaccine development.
|Park, Sang Hyun; Zhang, Yong; Kwon, Dongjin et al. (2018) Alcohol use effects on adolescent brain development revealed by simultaneously removing confounding factors, identifying morphometric patterns, and classifying individuals. Sci Rep 8:8297|
|Yanik, Elizabeth L; Hernández-Ramírez, Raúl U; Qin, Li et al. (2018) Brief Report: Cutaneous Melanoma Risk Among People With HIV in the United States and Canada. J Acquir Immune Defic Syndr 78:499-504|
|Stafman, Laura L; Williams, Adele P; Garner, Evan F et al. (2018) Targeting PIM Kinases Affects Maintenance of CD133 Tumor Cell Population in Hepatoblastoma. Transl Oncol 12:200-208|
|Garner, Evan F; Williams, Adele P; Stafman, Laura L et al. (2018) FTY720 Decreases Tumorigenesis in Group 3 Medulloblastoma Patient-Derived Xenografts. Sci Rep 8:6913|
|Owens, Michael A; Parker, Romy; Rainey, Rachael L et al. (2018) Enhanced facilitation and diminished inhibition characterizes the pronociceptive endogenous pain modulatory balance of persons living with HIV and chronic pain. J Neurovirol :|
|Ladowski, Joseph M; Reyes, Luz M; Martens, Gregory R et al. (2018) Swine Leukocyte Antigen Class II Is a Xenoantigen. Transplantation 102:249-254|
|Stringer, Kristi Lynn; Azuero, Andres; Ott, Corilyn et al. (2018) Feasibility and Acceptability of Real-Time Antiretroviral Adherence Monitoring among Depressed Women Living with HIV in the Deep South of the US. AIDS Behav :|
|Chakraborty, Asmi; Dorsett, Kaitlyn A; Trummell, Hoa Q et al. (2018) ST6Gal-I sialyltransferase promotes chemoresistance in pancreatic ductal adenocarcinoma by abrogating gemcitabine-mediated DNA damage. J Biol Chem 293:984-994|
|Hamilton, Jennie A; Wu, Qi; Yang, PingAr et al. (2018) Cutting Edge: Intracellular IFN-? and Distinct Type I IFN Expression Patterns in Circulating Systemic Lupus Erythematosus B Cells. J Immunol 201:2203-2208|
|Merlin, Jessica S; Long, Dustin; Becker, William C et al. (2018) Brief Report: The Association of Chronic Pain and Long-Term Opioid Therapy With HIV Treatment Outcomes. J Acquir Immune Defic Syndr 79:77-82|
Showing the most recent 10 out of 955 publications